Latest Insider Transactions at Immuno Gen, Inc. (IMGN)
This section provides a real-time view of insider transactions for Immuno Gen, Inc. (IMGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ImmunoGen, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ImmunoGen, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Richard John Wallace Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Feb 12
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
584,397
-100.0%
|
-
|
|
Feb 12
2024
|
Helen M. Thackray Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,074
-100.0%
|
-
|
|
Feb 12
2024
|
Dean J Mitchell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
103,000
-100.0%
|
-
|
|
Feb 12
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,039
-100.0%
|
-
|
|
Feb 12
2024
|
Stuart A Arbuckle Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,381
-100.0%
|
-
|
|
Feb 12
2024
|
Mark Alan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,720
-100.0%
|
-
|
|
Feb 12
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,723
-100.0%
|
-
|
|
Feb 12
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,274
-100.0%
|
-
|
|
Feb 12
2024
|
Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,327
-100.0%
|
-
|
|
Feb 12
2024
|
Daniel Char SVP & CHIEF LEGAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,000
-100.0%
|
-
|
|
Feb 05
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,583
-5.89%
|
$132,907
$29.3 P/Share
|
|
Feb 05
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
2,631
-15.16%
|
$76,299
$29.3 P/Share
|
|
Feb 05
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
20,107
-3.33%
|
$583,103
$29.28 P/Share
|
|
Feb 05
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
12,027
-36.37%
|
$348,783
$29.3 P/Share
|
|
Feb 02
2024
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,350
+15.56%
|
-
|
|
Feb 02
2024
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,435
+32.71%
|
-
|
|
Feb 02
2024
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,234
+7.81%
|
-
|
|
Feb 02
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
29,640
+47.27%
|
-
|
|
Jan 16
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
187,667
-98.21%
|
$5,442,343
$29.64 P/Share
|
|
Jan 16
2024
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
187,667
+30.76%
|
$938,335
$5.28 P/Share
|
|
Dec 29
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
367
+0.57%
|
$5,872
$16.01 P/Share
|
|
Dec 29
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+32.21%
|
$150,000
$5.32 P/Share
|
|
Dec 29
2023
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
569
+0.93%
|
$16,501
$29.65 P/Share
|
|
Dec 29
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
467
+4.98%
|
$7,472
$16.01 P/Share
|
|
Dec 29
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
615
+15.22%
|
$9,840
$16.01 P/Share
|
|
Dec 29
2023
|
Michael Vasconcelles EVP R&D & MEDICAL AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
1,327
+50.0%
|
$21,232
$16.01 P/Share
|
|
Dec 29
2023
|
Helen M. Thackray Director |
BUY
Grant, award, or other acquisition
|
Direct |
252
+7.58%
|
$7,308
$29.65 P/Share
|
|
Dec 29
2023
|
Stuart A Arbuckle Director |
BUY
Grant, award, or other acquisition
|
Direct |
442
+7.59%
|
$12,818
$29.65 P/Share
|
|
Dec 26
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
6,548
-43.65%
|
$189,892
$29.74 P/Share
|
|
Dec 22
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Dec 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
117,445
-97.66%
|
$3,405,905
$29.4 P/Share
|
|
Dec 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
117,445
+45.15%
|
$469,780
$4.94 P/Share
|
|
Nov 30
2023
|
Kristine Peterson Director |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$560,000
$28.9 P/Share
|
|
Nov 30
2023
|
Kristine Peterson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.67%
|
$220,000
$11.59 P/Share
|
|
Nov 30
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
3,826
-10.35%
|
$110,954
$29.2 P/Share
|
|
Nov 30
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
164,424
-98.32%
|
$4,603,872
$28.95 P/Share
|
|
Nov 30
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
164,424
+32.5%
|
$1,644,240
$10.72 P/Share
|
|
Nov 29
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
6,792
-70.73%
|
$108,672
$16.66 P/Share
|
|
Nov 29
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
6,792
+41.43%
|
$67,920
$10.65 P/Share
|
|
Nov 17
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
78,223
-67.91%
|
$1,251,568
$16.05 P/Share
|
|
Nov 17
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
78,223
+22.54%
|
$469,338
$6.31 P/Share
|
|
Nov 16
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,100
-9.98%
|
$65,600
$16.01 P/Share
|
|
Nov 16
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+4.76%
|
$24,600
$6.31 P/Share
|
|
Nov 15
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
26,286
-41.56%
|
$420,576
$16.01 P/Share
|
|
Nov 15
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
26,286
+17.16%
|
$157,716
$6.31 P/Share
|
|
Nov 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
166,725
-98.34%
|
$2,500,875
$15.85 P/Share
|
|
Nov 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
166,725
+49.58%
|
$666,900
$4.55 P/Share
|
|
Nov 07
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
19,517
-87.41%
|
$312,272
$16.66 P/Share
|
|
Nov 07
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
19,517
+46.64%
|
$195,170
$10.65 P/Share
|